Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study

Critical Care Medicine

Volumn 29, Issue 11, 2001, Pages 2081-2089

  Abraham, Edward ^a   Reinhart, Konrad ^b   Svoboda, Petr ^c   Seibert, Allan ^d   Olthoff, Derk ^e   Dal Nogare, Anthony ^f   Postier, Russell ^g   Hempelmann, Gunter ^h   Butler, Thomas ⁱ   Martin, Eike ^j   Zwingelstein, Christian ^k   Percell, Sandra ^k   Shu, Vincent ^l   Leighton, Anton ^k   Creasey, Abla A ^k  

^a UNIVERSITY OF COLORADO   (United States)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c Institute of Health Information and Statistics of the Czech Republic   (Czech Republic)

^d Mobile Diagnostic Center at Providence Park   (United States)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY HOSPITAL GIESSEN   (Germany)

ⁱ TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k NOVARTIS PHARMA AG   (Switzerland)

^l PFIZER INC   (United States)

more..

Author keywords

Clinical trial; Coagulation; Endothelial cells; International normalized ratio; Microvasculature; Recombinant tissue factor pathway inhibitor; Severe sepsis; Tissue factor pathway inhibitor

Indexed keywords

INTERLEUKIN 6; PLACEBO; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; INTERNATIONAL STANDARD UNIT; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SCORING SYSTEM; SEPSIS; SINGLE BLIND PROCEDURE;

EID: 0035159740     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200111000-00007     Document Type: Article

References (24)

1. Severe sepsis and septic shock definitions, epidemiology, and clinical manifestations
2. Pathogenesis of DIC in sepsis
3. Disseminated intravascular coagulation
4. Efficacy and safety of recombinant human activated protein C for severe sepsis
5. Structural design and molecular evaluation of a cytokine receptor family
6. Endothelial cell function and thrombosis
7. Ligand-induced protease receptor translocation into caveolae: A mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway
8. Tissue factor pathway inhibitor: Potential therapeutic applications
9. Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease
10. Endotoxin and thrombin elevate rodent epithelial cell protein C receptor mRNA levels and increase receptor shedding in vivo
11. Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: Evidence for proteolysis of cell surface molecules
12. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant
13. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
14. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon Gram-negative model of septic shock
15. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with Gram-negative peritonitis
16. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis
17. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14
18. Pharmacokinetics and pharmacodynamics (PK/PD) of recombinant tissue factor pathway inhibitor (rTFPI) in human volunteers
19. Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock
20. The SOFA (Sepsis-Related Organ Failure Assessment) score to describe organ dysfunction/failure
21. Tissue factor pathway inhibitor and the revised theory of coagulation
22. New potential therapeutic modalities: Tissue factor pathway inhibitor
23. Interferon increased HLA synthesis in melanoma cells: Interferon-resistant and sensitive cell lines
24. The sirens' songs of confirmatory sepsis trials: Selection bias and sampling error